Ascletis Pharma Inc. Publishes 2024 Annual Report
Ascletis Pharma Inc. has released its 2024 Annual Report, showcasing advancements in its metabolic disease pipeline, particularly the ASC30 oral tablet for obesity. The company plans to start a 13-week Phase IIa clinical study in the U.S. for ASC30 and complete a study for ASC47 with semaglutide. Financially, as of December 31, 2024, Ascletis reported cash and equivalents of approximately RMB1,980.8 million. The full report is available online.
Ascletis Pharma Inc. has published its annual report for the year 2024, highlighting significant progress in its metabolic disease pipeline. Key achievements include advancements in the ASC30 oral tablet for obesity, with a focus on demonstrating potential best-in-class characteristics. The company has announced plans to initiate a 13-week Phase IIa clinical study in the U.S. for ASC30 and to complete a clinical study for ASC47 in combination with semaglutide. Ascletis aims to strengthen early discovery efforts and seek license-out opportunities with global pharmaceutical companies. Financially, as of December 31, 2024, the Group reported cash and cash equivalents, along with other capital resources, amounting to approximately RMB1,980.8 million. The full report can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on April 28, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
